This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Compounds of the formula I



I

in which

X denotes C or N,

B denotes N, CH or C-CN,

R^1 denotes H, A, OH, NH_2, $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2,

R^2 if X = N is absent or

if X = C denotes H, A, Hal, CN, $-(CH_2)_p$-Ar, $-(CH_2)_p$-COOH, $-(CH_2)_p$-COOA, $-(CH_2)_p$-Het^3, $-(CH_2)_p$-NH_2, SO_2A, CHO or COA,

R^3 denotes H, A, -S-A, $-(CH_2)_p$-Ar, $-(CH_2)_p$-Het, NH-$(CH_2)_p$-Ar, NH-$(CH_2)_p$-Het, NH_2, NHA, NA_2, NH-alkylene-NH_2, NH-alkylene-NHA, NH-alkylene-NA_2 or NA-alkylene-NA_2,

R^4 denotes $-(CH_2)_s$-$(Ar^1)_n$-Y-R^6,

R^5 denotes H or CH_3,

R^4 and R^5 together also denote $Het^4-N<^{CH_2\text{-}CH_2\text{-}}_{CH_2\text{-}CH_2\text{-}}$,

R^6 denotes Het^4, $-(CH_2)_r$-NH_2, $-(CH_2)_r$-NHA or $-(CH_2)_r$-NA_2,

Y denotes O, S, $(CH_2)_q$ or NH,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A, $-CH_2$-COOH or $-OCH_2$-COOH,

Ar^1 denotes phenylene or piperazinediyl,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA_2, OA, COOA, CN, $-(CH_2)_p$-Ar, $-(CH_2)_t$-OH, $-(CH_2)_p$-Het^1 or carbonyl oxygen (=O),

Het^1 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O),

Het^2 denotes a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A,

Het^3 denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A,

Het^4 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, $CONH_2$, CONHA, $CONA_2$ or Ar^2,

Ar^2 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2 or SO_2A,

R^7, R^8, R^9, R^{10} each, independently of one another, denote H, A or $-(CH_2)_p$-Ar,

A denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

m denotes 0, 1, 2, 3 or 4,

n denotes 0 or 1,

p denotes 0, 1, 2, 3 or 4,

q denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

Hal denotes F, Cl, Br or I,

and, if X = C,

R^1 and R^2 together may also denote $-(CH_2)_4-$ or

R^2 and R^3 together may also denote $-(CHR^7-CHR^8-NR^9-CHR^{10})-$,

and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Original) Compounds according to Claim 1 in which

R^1 denotes A, OH, NH_2, $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2,

Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,

m denotes 0,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

3. (Currently Amended) Compounds according to Claim 1 ~~or 2~~ in which

R^4 denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,

s denotes 0 or 1,

n denotes 1,

Ar^1 denotes phenylene,

R^6 denotes Het^4,

Y denotes O,

Het^4 denotes pyridyl which is unsubstituted or monosubstituted by CONHA,

or benzo-1,2,5-thiadiazol-5-yl,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

4. (Currently Amended) Compounds according to ~~one or more of Claims 1-3~~ Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 1,
n	denotes 0,
Y	denotes $(CH_2)_q$,
q	denotes 0,
R^6	denotes Het^4,
Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole, 1,2,3-triazole, thienyl or furyl, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar^2,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

5. (Currently Amended) Compounds according to ~~one or more of Claims 1-4~~ Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 0,
Y	denotes $(CH_2)_q$,
q	denotes 0,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
r	denotes 1, 2, 3 or 4,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

6. (Currently Amended) Compounds according to ~~one or more of Claims 1-5~~ Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 1,
Ar^1	denotes phenylene,
Y	denotes O, $(CH_2)_q$ or NH,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
q	denotes 0, 1, 2, 3 or 4,
r	denotes 0, 1, 2, 3 or 4,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

7. (Currently Amended) Compounds according to ~~one or more of Claims 1-6~~ Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 1, 2, 3 or 4,
n	denotes 0,
Y	denotes $(CH_2)_q$,
q	denotes 0,
R^6	denotes Het^4,
Het^4	denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono-or disubstituted by A,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

8. (Currently Amended) Compounds according to ~~one or more of Claims 1-7~~ Claim 1 in which

R^1	denotes A, OH, NH_2, $-(CH_2)_m-Ar$,
m	denotes 0,
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,

R^2 if X = N is absent or

if X = C denotes CN,

R^3 denotes H, A, -S-A, phenyl or $-(CH_2)_p$-Het,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

9. (Currently Amended) Compounds according to ~~one or more of Claims 1-8~~ Claim 1 in which

R^1 denotes A, OH, NH_2, $-(CH_2)_m$-Ar,

m denotes 0,

Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,

R^2 if X = N is absent or

if X = C denotes CN,

R^3 denotes H, A, -S-A, phenyl or $-(CH_2)_p$-Het,

R^4 denotes $-(CH_2)_s-(Ar^1)_n$-Y-R^6,

s denotes 0,

n denotes 0,

Y denotes $(CH_2)_q$,

q denotes 0,

R^6 denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r$-NHA or $-(CH_2)_r-NA_2$,

r denotes 1, 2, 3 or 4,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

10. (Currently Amended) Compounds according to ~~one or more of Claims 1-9~~ Claim 1 in which

R^4 denotes $-(CH_2)_s-(Ar^1)_n$-Y-R^6,

s denotes 0,

n denotes 1,

Y denotes $(CH_2)_q$,

q denotes 0,

R^6 denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,

r denotes 0,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

11. (Currently Amended) Compounds according to ~~one or more of Claims 1-10~~ Claim 1 in which

R^4 denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,

s denotes 0,

n denotes 0 or 1,

Y denotes $(CH_2)_q$,

q denotes 0,

R^6 denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,

r denotes 0, 1, 2, 3 or 4,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

12. (Currently Amended) Compounds according to ~~one or more of Claims 1-11~~ Claim 1 in which

R^4 denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,

s denotes 0,

n denotes 0 or 1,

Y denotes $(CH_2)_q$,

R^6 denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,

Ar^1 denotes phenylene,

Y denotes O, $(CH_2)_q$ or NH,

q denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

13. (Currently Amended) Compounds according to ~~one or more of Claims 1-12~~ Claim 1 in which

R^1	denotes A, OH, NH_2, $-(CH_2)_m$-Ar,
m	denotes 0,
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,
R^2	if X = N is absent or
	if X = C denotes CN,
R^3	denotes H, A, -S-A, phenyl or $-(CH_2)_p$-Het,
R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 0 or 1,
Y	denotes $(CH_2)_q$,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r$-NHA or $-(CH_2)_r-NA_2$,
Ar^1	denotes phenylene,
Y	denotes O, $(CH_2)_q$ or NH,
q	denotes 0, 1, 2, 3 or 4,
r	denotes 0, 1, 2, 3 or 4,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

14. (Currently Amended) Compounds according to ~~one or more of Claims 1-13~~ Claim 1 in which

R^1	denotes A, OH, NH_2, $-(CH_2)_m$-Ar,
m	denotes 0,
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,
R^2	if X = N is absent or
	if X = C denotes CN,
R^3	denotes H, A, -S-A, phenyl or $-(CH_2)_p$-Het,

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 1,
Ar^1	denotes phenylene,
R^6	denotes Het^4,
Y	denotes O,
Het^4	denotes pyridyl which is unsubstituted or monosubstituted by CONHA, or benzo-1,2,5-thiadiazol-5-yl,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

15. (Currently Amended) Compounds according to ~~one or more of Claims 1-14~~ Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0 or 1,
n	denotes 0 or 1,
Y	denotes O or $(CH_2)_q$,
q	denotes 0,
R^6	denotes Het^4,
Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole, 1,2,3-triazole, thienyl or furyl, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar^2,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
Ar^1	denotes phenylene,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

16. (Currently Amended) Compounds according to ~~one or more of Claims 1-15~~ Claim 1 in which

Het denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, -$(CH_2)_t$-OH or -$(CH_2)_p$-Het^1,

Het^1 denotes an unsubstituted monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms,

or  ,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

17. (Currently Amended) Compounds according to ~~one or more of Claims 1-16~~ Claim 1 in which

Het denotes piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, pyridyl or furyl, which are unsubstituted or may be mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, -$(CH_2)_t$-OH or -$(CH_2)_p$-Het^1,

Het^1 denotes morpholinyl, pyrrolidinyl, pyridyl

or  ,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

18. (Currently Amended) Compounds according to ~~one or more of Claims 1-17~~ Claim 1 in which

R^4 denotes -$(CH_2)_s$-$(Ar^1)_n$-Y-R^6,

s	denotes 0 or 1,
n	denotes 0 or 1,
Y	denotes O, $(CH_2)_q$ or NH,
Ar^1	denotes phenylene,
q	denotes 0, 1, 2, 3 or 4,
R^6	denotes Het^4, $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
r	denotes 0, 1, 2, 3 or 4,
Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole, 1,2,3-triazole, thienyl or furyl, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar^2,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

19. (Currently Amended) Compounds according to ~~one or more of Claims 1-18~~ Claim 1 in which

R^1	denotes A, OH, NH_2, $-(CH_2)_m-Ar$,
m	denotes 0,
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,
R^2	if X = N is absent or if X = C denotes CN,
R^3	denotes H, A, -S-A, phenyl or $-(CH_2)_p$-Het,
Het	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, $-(CH_2)_t$-OH or $-(CH_2)_p-Het^1$,
Het^1	denotes an unsubstituted monocyclic saturated or aromatic

heterocycle having 1 to 2 N and/or O atoms,

or  ,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

20. (Currently Amended) Compounds according to ~~one or more of Claims 1-19~~ Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0, 1, 2, 3 or 4,
n	denotes 0 or 1,
Y	denotes O or $(CH_2)_q$,
Ar^1	denotes phenylene,
q	denotes 0,
R^6	denotes Het^4, $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
r	denotes 0, 1, 2, 3 or 4,
Het^4	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, $CONH_2$, CONHA, $CONA_2$ or Ar^2,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

21. (Currently Amended) Compounds according to ~~one or more of Claims 1-20~~ Claim 1 in which

Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine, thiazole or imidazole, each of which is unsubstituted or

monosubstituted by CONHA, A and/or Ar^2,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

22. (Currently Amended) Compounds according to ~~one or more of Claims 1-21~~ Claim 1 in which

R^4 denotes 4-(pyridin-4-yloxy)phenyl, 4-(pyridin-4-yloxy)-phenylmethyl or 4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl, where the pyridine radical may be substituted by $CONHCH_3$,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

23. (Currently Amended) Compounds according to ~~one or more of Claims 1-22~~ Claim 1 in which

Het^1 denotes an unsubstituted monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms,

or  ,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

24. (Currently Amended) Compounds according to ~~one or more of Claims 1-23~~ Claim 1 in which

Het^1 denotes morpholinyl, pyrrolidinyl, piperidinyl, pyridyl

or  ,

and pharmaceutically usable derivatives, solvates, tautomers, salts and

stereoisomers thereof, including mixtures thereof in all ratios.

25. (Currently Amended) Compounds according to ~~one or more of Claims 1-24~~ Claim 1 in which

Het^2 denotes an unsubstituted monocyclic aromatic heterocycle having 1-2 N, O and/or S atoms,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

26. (Currently Amended) Compounds according to ~~one or more of Claims 1-25~~ Claim 1 in which

R^1 denotes A, OH, NH_2, $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2,

m denotes 0,

Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,

R^2 if X = N is absent or

if X = C

denotes H, CN, COOA or phenyl,

R^3 denotes H, A, -S-A, phenyl, NH-benzyl, $-(CH_2)_p$-Het, NH-$(CH_2)_p$-Het, NA_2, NH-alkylene-NA_2 or NA-alkylene-NA_2,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

27. (Currently Amended) Compounds according to ~~one or more of Claims 1-26~~ Claim 1 in which

R^2 if X = N is absent or

if X = C

denotes H, CN, $(CH_2)_oAr''$, $(CH_2)_oCOOA$ or SO_2A,

Ar'' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal or OA,

o denotes 0 or 1,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

28. (Currently Amended) Compounds according to ~~one or more of Claims 1-27~~ Claim 1 in which

R^1 denotes A, OH, NH_2, $-(CH_2)_m$-Ar' or $-(CH_2)_m$-Het^2,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OA, A or COOA,

m denotes 0,

Het^2 denotes thienyl, furyl, imidazolyl, pyrrolyl, thiazolyl or pyridyl,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

29. (Currently Amended) Compounds according to ~~one or more of Claims 1-28~~ Claim 1 in which

X denotes C or N,

B denotes N, CH or C-CN,

R^1 denotes A, OH, NH_2, $-(CH_2)_m$-Ar' or $-(CH_2)_m$-Het^2,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OA, A or COOA,

m denotes 0,

Het^2 denotes thienyl, furyl, imidazolyl, pyrrolyl, thiazolyl or pyridyl,

R^2 if X = N is absent or

if X = C

denotes H, CN, $(CH_2)_o$Ar'', $(CH_2)_o$COOA or SO_2A,

Ar'' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal or OA,

o denotes 0 or 1,

R^3 denotes H, A, -S-A, phenyl, NH-benzyl, $-(CH_2)_p$-Het, NH-$(CH_2)_p$-Het, NA_2, NH-alkylene-NA_2 or

NA-alkylene-NA_2,

Het denotes piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, pyridyl or furyl, which are unsubstituted or may be mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, $-(CH_2)_t$-OH or $-(CH_2)_p$-Het^1,

Het^1 denotes morpholinyl, pyrrolidinyl, pyridyl

or  ,

R^4 denotes $-(CH_2)_s$-$(Ar^1)_n$-Y-R^6,

Y denotes O or $(CH_2)_q$,

R^5 denotes H or CH_3,

R^4 and R^5 together also denote  ,

R^6 denotes Het^4, $-(CH_2)_r$-NH_2, $-(CH_2)_r$-NHA or $-(CH_2)_r$-NA_2,

Het^4 denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine, thiazole or imidazole, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar^2,

Ar^1 denotes phenylene or piperazinediyl,

Ar^2 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,

R^7, R^8, R^9, R^{10} each, independently of one another, denote H, A or $-(CH_2)_p$-Ar,

A denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

n denotes 0 or 1,

p denotes 0, 1, 2, 3 or 4,

q denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

t denotes 1, 2, 3 or 4,

Hal denotes F, Cl, Br or I,

and, if X = C,

R^1 and R^2 together may also denote $-(CH_2)_4-$ or

R^2 and R^3 together may also denote $-(CHR^7-NR^8-CHR^9-CHR^{10})-$,

and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

30. (Currently Amended) Compounds according to ~~one or more of Claims 1-29~~ Claim 1 in which

X denotes C or N,

B denotes N, CH or C-CN,

R^1 denotes A, OH, NH_2, $-(CH_2)_m$-Ar' or $-(CH_2)_m$-Het^2,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OA, A or COOA,

m denotes 0,

Het^2 denotes an unsubstituted monocyclic aromatic heterocycle having 1-2 N, O and/or S atoms,

R^2 if X = N is absent or

if X = C

denotes H, CN, $(CH_2)_o$Ar'', $(CH_2)_o$COOA or SO_2A,

Ar'' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal or OA,

o denotes 0 or 1,

R^3 denotes H, A, -S-A, phenyl, NH-benzyl, $-(CH_2)_p$-Het, NH-$(CH_2)_p$-Het, NA_2, NH-alkylene-NA_2 or NA-alkylene-NA_2,

Het denotes a monocyclic saturated or aromatic heterocycle having

1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, -$(CH_2)_t$-OH or -$(CH_2)_p$-Het^1,

Het^1 denotes morpholinyl, pyrrolidinyl, pyridyl

or  ,

R^4 denotes -$(CH_2)_s$-$(Ar^1)_n$-Y-R^6,

Y denotes O or $(CH_2)_q$,

R^5 denotes H or CH_3,

R^4 and R^5 together also denote  ,

R^6 denotes Het^4, -$(CH_2)_r$-NH_2, -$(CH_2)_r$-NHA or -$(CH_2)_r$-NA_2,

Het^4 denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, $CONH_2$, CONHA, $CONA_2$ or Ar^2,

Ar^1 denotes phenylene or piperazinediyl,

Ar^2 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,

R^7, R^8, R^9, R^{10} each, independently of one another, denote H, A or -$(CH_2)_p$-Ar,

A denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

n denotes 0 or 1,

p denotes 0, 1, 2, 3 or 4,

q denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

t denotes 1, 2, 3 or 4,

Hal denotes F, Cl, Br or I,

and, if X = C,

R^1 and R^2 together may also denote $-(CH_2)_4-$ or

R^2 and R^3 together may also denote $-(CHR^7-NR^8-CHR^9-CHR^{10})-$,

and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

31. (Currently Amended) Compounds according to ~~one or more of Claims 1-30~~ Claim 1 in which

X denotes N,

B denotes N, CH or C-CN,

R^1 denotes NH_2,

R^2 is absent,

R^3 denotes H, A, -S-A, phenyl, NH-benzyl, $-(CH_2)_p$-Het, $NH-(CH_2)_p$-Het, NA_2, NH-alkylene-NA_2 or NA-alkylene-NA_2,

Het denotes piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, pyridyl or furyl, which are unsubstituted or may be mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, $-(CH_2)_t$-OH or $-(CH_2)_p$-Het^1,

Het^1 denotes morpholinyl, pyrrolidinyl, pyridyl

or  ,

R^4 denotes $-(CH_2)_s-(Ar^1)_n$-Y-R^6,

Y	denotes O or $(CH_2)_q$,
R^5	denotes H or CH_3,
R^4 and R^5	together also denote  ,
R^6	denotes Het^4, $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine, thiazole or imidazole, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar^2,
Ar^1	denotes phenylene or piperazinediyl,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
A	denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
n	denotes 0 or 1,
p	denotes 0, 1, 2, 3 or 4,
q	denotes 0, 1, 2, 3 or 4,
r	denotes 0, 1, 2, 3 or 4,
s	denotes 0, 1, 2, 3 or 4,
t	denotes 1, 2, 3 or 4,
Hal	denotes F, Cl, Br or I,

and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

32. (Currently Amended) Compounds according to ~~one or more of Claims 1-31~~ Claim 1 in which

X	denotes N,
B	denotes N, CH or C-CN,
R^1	denotes NH_2,

R^2	is absent,
R^3	denotes H, A, -S-A, phenyl, NH-benzyl, -$(CH_2)_p$-Het, NH-$(CH_2)_p$-Het, NA_2, NH-alkylene-NA_2 or NA-alkylene-NA_2,
Het	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, -$(CH_2)_t$-OH or -$(CH_2)_p$-Het^1,
Het^1	denotes morpholinyl, pyrrolidinyl, pyridyl
or	 ,
R^4	denotes -$(CH_2)_s$-$(Ar^1)_n$-Y-R^6,
Y	denotes O or $(CH_2)_q$,
R^5	denotes H or CH_3,
R^4 and R^5	together also denote  ,
R^6	denotes Het^4, -$(CH_2)_r$-NH_2, -$(CH_2)_r$-NHA or -$(CH_2)_r$-NA_2,
Het^4	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, $CONH_2$, CONHA, $CONA_2$ or Ar^2,
Ar^1	denotes phenylene or piperazinediyl,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
A	denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
n	denotes 0 or 1,
p	denotes 0, 1, 2, 3 or 4,

q denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

t denotes 1, 2, 3 or 4,

Hal denotes F, Cl, Br or I,

and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

33. (Original) Compounds according to Claim 1, selected from the group

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,





(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(7-methyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methyl-aminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(5,7-bistrifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

(2-phenylthiazol-4-ylmethyl)-(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,

(2-phenylthiazol-4-ylmethyl)-(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(pyridin-4-yloxy)benzyl]amine,

(3-dimethylaminopropyl)-(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,

7-phenyl-2-[4-(pyridin-4-yloxy)phenylamino]-5-trifluoromethyl-pyrazool[1,5-a]pyrimidine-3-carbonitrile,

7-methyl-2-[4-(pyridin-4-yloxy)phenylamino]-5-trifluoromethyl-pyrazolo[1,5-a]pyrimidine-3-carbonitrile,

5,7-dimethyl-2-[4-(pyridin-4-yloxy)phenylamino]pyrazolo[1,5-a]-pyrimidine-3-carbonitrile,

7-phenyl-2-[4-(pyridin-4-yloxy)phenylmethylamino]-5-trifluoromethyl-pyrazolo[1,5-a]pyrimidine-3-carbonitrile,





,



,





,



,



,



6-benzyl-2-[3-(4-methylpiperazin-1-yl)propylamino]-5,6,7,8-tetrahydro-1,3,3a,6,9-pentaazacyclopenta[b]naphthalen-4-ol,





,



,



,



,



,



,



















































































,



,



,



,



,















,



,



,



,



,



,



,



,



,



,



,














,


,


,


,


,

























































and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

34. (Currently Amended) Process for the preparation of compounds of the formula I according to ~~Claims 1-33~~ Claim 1 and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, characterised in that

a) for the preparation of compounds of the formula I

in which X denotes C, a compound of the formula II



II

,

in which R^4, R^5 and B have the meanings indicated in Claim 1,

i) is reacted with a compound of the formula IIIa



IIIa

,

in which R^1 OA and

R^2 and R^3 have the meanings indicated in Claim 1,

or

ii) with a compound of the formula IIIb



IIIb

,

in which R^1, R^2 and R^3 have the meanings indicated in Claim 1, and A denotes alkyl having 1, 2, 3 or 4 C atoms,

or

iii) with a compound of the formula IIIc



IIIc

,

in which

R^1, besides the meanings indicated in Claim 1, also denotes OA,
R^2 and R^3 have the meanings indicated in Claim 1,
and A, A' each, independently of one another, denote alkyl having 1, 2, 3 or 4 C atoms,

or A and A' together may also form a butylene or pentylene chain,

or

b) for the preparation of compounds of the formula I

in which X denotes N and R^1 denotes NH_2,

a compound of the formula II is reacted with a compound of the formula IIId



IIId

in which R^3 has the meaning indicated in Claim 1,

and A denotes alkyl having 1, 2, 3 or 4 C atoms,

or

c) for the preparation of compounds of the formula I in which

X denotes N,

R^1 denotes H, A, $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2,

R^3 denotes -S-A

a compound of the formula II is reacted with a compound of the formula IIIe



IIIe

in which

R^1 denotes H, A, $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2

and A denotes alkyl having 1, 2, 3 or 4 C atoms,

and/or that one or more radical(s) R^1,R^2 and/or R^3 in a compound of the formula I is (are) converted into one or more radical(s) R^1,R^2 and/or R^3,

by, for example,

i) converting an alkylsulfanyl group into an amine,

ii) hydrolysing an ester to the acid, reducing it to the aldehyde or alcohol,

iii) reducing a nitrile to the aldehyde or amine,

and/or

a base or acid of the formula I is converted into one of its salts.

35. (Original) Medicaments comprising at least one compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

36. (Original) Use of compounds according to Claim 1 and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios,

for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role.

37. (Original) Use according to Claim 36, where the kinases are selected from the group of the tyrosine kinases.

38. (Original) Use according to Claim 37, where the tyrosine kinases are TIE-2, VEGFR, PDGFR, FGFR and/or FLT/KDR.

39. (Currently Amended) Use according to Claim 37 ~~of compounds according to Claim 1~~, and pharmaceutically usable derivatives, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of tyrosine kinases ~~by the compounds according to Claim 1~~.

40. (Currently Amended) Use according to Claim 39 for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of TIE-2, VEGFR, PDGFR, FGFR and/or FLT/KDR ~~by the compounds according to Claim 1~~.

41. (Currently Amended) Use according to Claim 39 ~~or 40~~, where the disease to be treated is a solid tumour.

42. (Original) Use according to Claim 41, where the solid tumour originates from the group of tumours of the squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach, the larynx and/or the lung.

43. (Original) Use according to Claim 41, where the solid tumour originates from the group monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma.

44. (Original) Use according to Claim 41, where the solid tumour originates from the group of lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma.

45. (Currently Amended) Use according to Claim 39 ~~or 40~~, where the disease to be treated is a tumour of the blood and immune system.

46. (Original) Use according to Claim 45, where the tumour originates from the group of acute myelotic leukaemia, chronic myelotic leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.

47. (Currently Amended) Use according to Claim 39 ~~or 40~~ for the treatment of a disease in which angiogenesis is implicated.

48. (Original) Use according to Claim 47, where the disease is an ocular disease.

49. (Currently Amended) Use according to Claim 39 ~~or 40~~ for the treatment of retinal vascularisation, diabetic retinopathy, age-induced macular degeneration and/or inflammatory diseases.

50. (Original) Use according to Claim 49, where the inflammatory disease originates from the group rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reactions.

51. (Currently Amended) Use according to Claim 39 ~~or 40~~ for the treatment of bone pathologies, where the bone pathology originates from the group osteosarcoma, osteoarthritis and rickets.

52. (Original) Use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumours, where a therapeutically effective amount of a compound of the formula I is administered in combination with a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) another angiogenesis inhibitor.

53. (Original) Use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumours, where a therapeutically effective amount of a compound of the formula I is administered in combination with radiotherapy and a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) another angiogenesis inhibitor.

54. (Currently Amended) Use according to Claim 39 ~~or 40~~ for the preparation of a medicament for the treatment of diseases which are based on disturbed TIE-2 activity,
where a therapeutically effective amount of ~~a~~ said compound ~~according to Claim 1~~ is administered in combination with a growth-factor receptor inhibitor.

55. (Original) Intermediate compounds of the formula I-1



I-1

in which

B denotes N, CH or C-CN,

R^4 denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,

R^5 denotes H or CH_3,

R^4 and R^5 together also denote  ,

Y denotes O, S, $(CH_2)_q$ or NH,

Ar^1 denotes phenylene or piperazinediyl,

Het^4 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, $CONH_2$, CONHA, $CONA_2$ or Ar^2,

Ar^2 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2 or SO_2A,

A denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

n denotes 0 or 1,

q denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

Hal denotes F, Cl, Br or I,

and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms,

and solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

56. (Original) Intermediate compounds according to Claim 55 in which

B denotes N, CH or C-CN,

R^4 denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,

Y denotes O or $(CH_2)_q$,

R^5 denotes H or CH_3,

R^4 and R^5 together also denote  ,

R^6 denotes Het^4, $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,

Het^4 denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine, thiazole or imidazole, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar^2,

Ar^1 denotes phenylene or piperazinediyl,

Ar^2 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,

A denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

n denotes 0 or 1,

q denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

Hal denotes F, Cl, Br or I,

and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms,

and solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

57. (Currently Amended) Intermediate compounds according to Claim 55 ~~or 56~~, selected from the group

N-[4-(pyridin-4-yloxy)phenyl]-4*H*-1,2,4-triazole-3,5-diamine,

N-{4-[2-(N-methylaminocarbonyl)pyridin-4-yloxy]phenyl}-4*H*-1,2,4-triazole-3,5-diamine,

N-{3-[2-(N-methylaminocarbonyl)pyridin-4-yloxy]phenyl}-4*H*-1,2,4-triazole-3,5-diamine,

N-[4-(pyridin-4-yloxy)phenylmethyl]-4*H*-1,2,4-triazole-3,5-diamine,

N-(5-methyl-2-phenyl-2*H*-1,2,3-triazol-4-ylmethyl)-4*H*-1,2,4-triazole-3,5-diamine,

N-(2-phenylthiazol-4-ylmethyl)-4*H*-1,2,4-triazole-3,5-diamine,

N-[4-(2-diethylaminoethoxy)phenyl]-4*H*-1,2,4-triazole-3,5-diamine,

N-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]-4*H*-1,2,4-triazole-3,5-diamine,

N-[4-(pyridin-4-ylsulfanyl)phenyl]-4H-1,2,4-triazole-3,5-diamine,

5-amino-3-[4-(pyridin-4-yloxy)phenylamino]-1*H*-pyrazole-4-carbonitrile,

N*3*-[4-(pyridin-4-yloxy)phenyl]-1H-pyrazole-3,5-diamine,

and solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.